Healthcare / Medical DevicesNYSE American
$2.65
-0.02 (-0.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-19.8M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$22M
P/E
N/A
•EV/EBITDA
N/A
•ROE
68.2%
↑Gross Margin
N/A
•Debt/Equity
-0.33
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-1144.7%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.7M · net income $-23.4M · FCF $-19.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $1.7M | $1.7M | $1.2M | $775302.00 | $306392.00 | $90035.00 | $13433.00 | $17096.00 | — | — | — | — | $14785.00 | $54968.00 | $54968.00 | — |
| Net Income | $-23.4M | $-23.4M | $-27.0M | $-35.3M | $-30.3M | $-27.0M | $-20.4M | $-16.1M | $-18.0M | $-73.7M | $-11.9M | $-9.5M | $-8.2M | $-3.7M | $-4.1M | $-3.5M |
| EBITDA | $-19.8M | $-19.8M | $-25.6M | $-34.0M | $-29.2M | $-27.4M | $-20.5M | $-15.4M | $-17.3M | $-14.2M | $-12.1M | $-9.8M | $-5.8M | $-4.4M | $-3.9M | $-2.5M |
| EPS | -4.40 | -4.40 | -6.20 | -10.00 | -11.00 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -1228.6% | -1228.6% | -2182.5% | -4614.1% | -9971.1% | -31469.0% | -158176.2% | -93840.2% | — | — | — | — | -40258.4% | -8324.7% | -7428.0% | — |
| Net Margin | -1352.2% | -1352.2% | -2186.3% | -4555.5% | -9879.1% | -29977.0% | -151859.6% | -94168.5% | — | — | — | — | -55553.1% | -6749.9% | -7428.0% | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | -0.33 | -0.33 | -0.23 | -0.75 | -1.93 | 0.13 | 0.16 | 0.15 | 0.16 | 0.13 | 0.02 | 0.00 | — | — | — | — |
| Current Ratio | 0.17 | 0.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-19.8M | $-19.8M | $-26.5M | $-19.1M | $-16.8M | $-21.8M | $-18.4M | $-13.3M | $-14.4M | $-13.6M | $-9.3M | $-8.6M | $-4.4M | $-3.1M | $-2.4M | $-1.7M |
| Returns | ||||||||||||||||
| ROE | 68.2% | 68.2% | 108.3% | 452.7% | 1175.5% | -152.3% | -125.2% | -113.4% | -148.3% | -740.1% | -56.2% | -157.7% | -2230.9% | -545.1% | -489.7% | -321.6% |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 40.0% | 40.0% | 59.1% | 153.0% | — | 570.3% | -21.4% | — | — | — | — | — | -73.1% | 0.0% | — | — |
| EPS Growth | 29.0% | 29.0% | 38.0% | 9.1% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-73.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.20 → -4.40
Residual
-73.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.